2017 Medical science Side effects 
European Pharmaceutical Review
MAY 23, 2024
In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector. Most recently, Imran has served as Medical Science Liaison (MSL) Head, Oncology U.S.
European Pharmaceutical Review
AUGUST 15, 2024
BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. 2017; 1(20):1739–48. 2022; 21(1).
Expert insights. Personalized for you.
110 
Let's personalize your content